ViroGates' capital raise of DKK 13.9 million and issue of 3,097,047 new shares have been registered

19.12.2023 16:03:14 CET | ViroGates | Changes in share capital and votes

COMPANY ANNOUNCEMENT - No. 23-2023 -19 December 2023

BIRKERØD, DENMARK – ViroGates A/S (“ViroGates” or the “Company”) announces that the capital raise of approximately DKK 13.9 million has been completed. The issue of 3,097,047 new shares at a price of DKK 4.5 per share has been registered with the Danish Business Authority.

Prior to the increase, the Company’s share capital amounted to DKK 3,350,507, consisting of 3,350,507 shares of nominally DKK 1 each. After the nominal increase of DKK 3,097,047, the Company’s share capital now amounts to DKK 6,447,554, consisting of 6,447,554 shares of nominally DKK 1 each.

The change in share capital is reflected in the Company’s articles of association available on the Company’s website.

ViroGates further expects that the first day of trading of the new shares on Nasdaq First North Growth Market Denmark is 21 December 2023.

For further information, please contact:

ViroGates A/S:

CEO, Jakob Knudsen

Tel. [phone], email: [e-mail]

Certified Advisor:

Västra Hamnen Corporate Finance

Per Lönn

Tel. [phone], email: [e-mail]

About ViroGates

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs, and empower clinical staff.

The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.

Disclosure regulation

Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.

Contacts

• Jakob Knudsen, CEO, [phone], [e-mail]

Attachments

• 20231219 -ViroGates Company ann. 23.pdf

© Ritzau Denmark, source Ritzau English Regulatory Releases